Results 231 to 240 of about 152,178 (350)

Treatment‐Related and Immune‐Related Adverse Events Associated With Immune Checkpoint Inhibitor‐Based Combination Therapies for Breast Cancer: A Systematic Review and Meta‐Analysis

Thoracic Cancer, Volume 17, Issue 3, February 2026.
This systematic review and meta‐analysis (100 trials, 9192 patients) clarifies breast cancer ICI‐based combination toxicity hierarchies. ICI‐ADC has higher grade ≥ 3 TRAEs; ICI‐mTKI has the worst irAEs, while ICI‐PARPi/HER2‐targeted combinations present the lowest risks.
Yunwei Lu, Huan Li, Ke Li, Yiting Chen, Shu Wang   +4 more
wiley   +1 more source

High levels of circulating miR-19a-3p in patients with metastatic HER2 + breast cancer are associated with a favorable prognosis and anti-tumor immune responses. [PDF]

Breast Cancer Res
Cohen EN, Gao H, Tin S, Wu Q, Ivan C, Ueno NT, Woodward WA, Reuben JM, Anfossi S.   +8 more
europepmc   +1 more source

Abemacilib‐Related Radiation Recall Dermatitis Post Breast Reconstruction: A Case Report and Literature Review

Thoracic Cancer, Volume 17, Issue 3, February 2026.
Radiation recall dermatitis (RRD)—an inflammatory reaction in previously irradiated skin triggered by subsequent systemic therapy. This report presents a case of a breast cancer patient who developed injection port exposure following radiotherapy after breast reconstruction; subsequent oral administration of abemaciclib led to the occurrence and rapid ...
Zhaobo Jia, Lijin Gao, Xiaochuan Tang, Xinzhong Chang   +3 more
wiley   +1 more source

Treatment patterns, health care resource utilization and costs, and clinical outcomes among older adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma. [PDF]

J Manag Care Spec Pharm
Wang L, Wang A, Valderrama A, Wang T, Mattera M, Zhou ZY, Sharan KP, Pintova S.   +7 more
europepmc   +1 more source

Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial

, 2021
Amy A. Kirkham, Edith Pituskin, Richard B. Thompson, John R. Mackey, Sheri L. Koshman, Davinder S. Jassal, Marshall Pitz, Mark J. Haykowsky, Joseph J. Pagano, Kelvin Chow, Albert K.Y. Tsui, Justin A. Ezekowitz, Gavin Y. Oudit, D. Ian Paterson   +13 more
openalex   +2 more sources

Liquid–Liquid Phase Separation in Major Hallmarks of Cancer

Cell Proliferation, Volume 59, Issue 2, February 2026.
Aberrant condensates formed through phase separation are involved in the dysregulation of various critical cellular processes, including genome stability, transcriptional regulation and signal transduction, thereby promoting malignant transformation and the acquisition of multiple cancer hallmarks.
Chen‐chen Xie, Ting Wang, Xin‐ran Liu, Yan Wang, Qin Dang, Tian Ding, Jia‐qi Xu, Xian‐jun Yu, Hai Lin, Xiao‐wu Xu, Yi Qin   +10 more
wiley   +1 more source

Maintenance therapy in hormone receptor-positive and human epidermal growth factor receptor 2-positive metastatic breast cancer: a real-world multicenter retrospective study. [PDF]

Front Oncol
Bao S, Chen J, Yin Y.
europepmc   +1 more source

p-NO₂–Bn–H₄neunpa and H₄neunpa–Trastuzumab: Bifunctional Chelator for Radiometalpharmaceuticals and ¹¹¹In Immuno-Single Photon Emission Computed Tomography Imaging

, 2017
Sarah Spreckelmeyer, Caterina F. Ramogida, Julie Rousseau, Karen Arane, Ivica Bratanovic, Nadine Colpo, Una Jermilova, Gemma Dias, Iulia Dude, Marı́a de Guadalupe Jaraquemada-Peláez, François Bénard, Paul Schaffer, Chris Orvig   +12 more
openalex   +2 more sources

166P Adjuvant trastuzumab plus pertuzumab (TP) versus trastuzumab (T) alone in patients achieving pathologic complete response after chemotherapy with TP

, 2022
Jong Hoon Kim, Yoonwon Kook, Junyoung Jang, Soong June Bae, Byung Joo Chae, Dongwon Shin, Jai Min Ryu, Joohyuk Sohn, Joon Jeong, Sung Gwe Ahn   +9 more
openalex   +2 more sources

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy

European Journal of Haematology, Volume 116, Issue 2, Page 104-115, February 2026.
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley   +1 more source